


Repaglinide

Cat. No.:	HY-15209		
CAS No.:	135062-02-1		
Molecular Formula:	C ₂₇ H ₃₆ N ₂ O ₄		
Molecular Weight:	452.59		
Target:	Potassium Channel		
Pathway:	Membrane Transporter/Ion Channel		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 50 mg/mL (110.48 mM)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	2.2095 mL	11.0475 mL	22.0951 mL
	5 mM	0.4419 mL	2.2095 mL	4.4190 mL
	10 mM	0.2210 mL	1.1048 mL	2.2095 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.5 mg/mL (5.52 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: ≥ 2.5 mg/mL (5.52 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.5 mg/mL (5.52 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Repaglinide is an insulin secretagogue for the treatment of type-2 diabetes mellitus^[1].

In Vitro

Repaglinide reduces postprandial glucose levels by enhancing the early phase of insulin secretion and increasing the total amount of insulin secreted^[1].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Repaglinide (AG-EE 623ZW) is very rapidly absorbed (t_{\max} less than 1 hour) with a $t_{1/2}$ of less than one hour. Furthermore, Repaglinide is inactivated in the liver and more than 90 % excreted via the bile. Repaglinide (1 mg/kg p.o.) is effective ($P < 0.001$) as an insulin-releasing agent in a rat model (low-dose streptozotocin) of type 2 diabetes. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Wang LC, et al. Characteristics of repaglinide and its mechanism of action on insulin secretion in patients with newly diagnosed type-2 diabetes mellitus. *Medicine* (Baltimore). 2018 Sep;97(38):e12476.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA